Drug Profile
SR 29001
Latest Information Update: 15 Sep 1998
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class Hormones
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Growth disorders
Most Recent Events
- 15 Sep 1998 Discontinued-preregistration for Growth disorders in European Union (Unknown route)
- 23 Dec 1996 Preregistration for Growth disorders in European Union (Unknown route)
- 04 Sep 1996 Investigation in Growth disorders in France (Unknown route)